Cargando…

A Phase II Trial of Selinexor (KPT‐330) for Metastatic Triple‐Negative Breast Cancer

LESSONS LEARNED. Single‐agent selinexor has limited activity in heavily pretreated patients with metastatic triple‐negative breast cancer. Selinexor 60 mg by mouth twice weekly was generally well tolerated with a side‐effect profile consistent with previous clinical trials. Future studies of selinex...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shafique, Michael, Ismail‐Khan, Roohi, Extermann, Martine, Sullivan, Dan, Goodridge, Dawn, Boulware, David, Hogue, Deanna, Soliman, Hatem, Khong, Hung, Han, Hyo S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2019
Materias:	Clinical Trial Results
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656474/ https://www.ncbi.nlm.nih.gov/pubmed/30996012 http://dx.doi.org/10.1634/theoncologist.2019-0231

Ejemplares similares

Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma
por: Garg, Manoj, et al.
Publicado: (2016)

Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer
por: Arango, Natalia Paez, et al.
Publicado: (2017)

Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor
por: Subhash, Vinod Vijay, et al.
Publicado: (2018)

Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin
por: Garg, Manoj, et al.
Publicado: (2017)

A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone‐ and/or Enzalutamide‐Refractory Metastatic Castration‐Resistant Prostate Cancer
por: Wei, Xiao X., et al.
Publicado: (2018)

Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
por: Tremblay, Gabriel, et al.
Publicado: (2021)

Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S‐1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma
por: Akahori, Takahiro, et al.
Publicado: (2019)

KPT-330 has antitumour activity against non-small cell lung cancer
por: Sun, H, et al.
Publicado: (2014)

Selective nuclear export inhibitor KPT‑330 enhances the radiosensitivity of esophageal carcinoma cells
por: Xu, Jing, et al.
Publicado: (2023)

Nab-paclitaxel Followed by Dose-dense Epirubicin/Cyclophosphamide in Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Phase II Study
por: Liu, Yin, et al.
Publicado: (2022)

Cisplatin/Tegafur/Uracil/Irinotecan Triple Combination Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: A Phase I/II Clinical Study
por: Chen, San-Chi, et al.
Publicado: (2016)

Analysis of Differentially Expressed MicroRNAs and Circulating Tumor Cells as Predictive Biomarkers of Platinum Chemoresistance in Primary Ovarian Carcinomas: A Prospective Study
por: Lou, Emil, et al.
Publicado: (2019)

KPT-330 inhibition of chromosome region maintenance 1 is cytotoxic and sensitizes chronic myeloid leukemia to Imatinib
por: Nie, Danian, et al.
Publicado: (2018)

A Phase II Multi‐Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma
por: Burotto, Mauricio, et al.
Publicado: (2017)

A Phase I Study of Ganetespib and Ziv‐Aflibercept in Patients with Advanced Carcinomas and Sarcomas
por: Meehan, Robert, et al.
Publicado: (2018)

KPT‐330 and Y219 exert a synergistic antitumor effect in triple‐negative breast cancer through inhibiting NF‐κB signaling
por: Wen, Tiantian, et al.
Publicado: (2023)

A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer
por: Chiappori, Alberto A., et al.
Publicado: (2016)

KPT330 improves Cas9 precision genome- and base-editing by selectively regulating mRNA nuclear export
por: Cui, Yan-ru, et al.
Publicado: (2022)

Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer
por: Agarwal, Neeraj, et al.
Publicado: (2016)

A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
por: Bendell, Johanna C., et al.
Publicado: (2016)

Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma
por: Piperno-Neumann, Sophie, et al.
Publicado: (2016)

Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors
por: Olszanski, Anthony J., et al.
Publicado: (2016)

A Phase I Study of the Safety and Pharmacokinetics of Higher-Dose Icotinib in Patients With Advanced Non-Small Cell Lung Cancer
por: Liu, Jian, et al.
Publicado: (2016)

A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone
por: Lin, Jianqing, et al.
Publicado: (2016)

Phase II Trial of Abiraterone Acetate Plus Prednisone in Black Men With Metastatic Prostate Cancer
por: Tsao, Che-Kai, et al.
Publicado: (2016)

Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-Based Therapy
por: Machiels, Jean-Pascal, et al.
Publicado: (2016)

A Phase I Dose‐Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low‐Grade or Intermediate‐Grade B‐Cell or T‐Cell Lymphoma
por: Foss, Francine Marie, et al.
Publicado: (2018)

Chemoprevention in Patients with Peutz‐Jeghers Syndrome: Lessons Learned
por: de Brabander, Justin, et al.
Publicado: (2018)

Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan‐Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
por: Edelman, Gerald, et al.
Publicado: (2018)

A Randomized, Double‐Blinded, Phase II Trial of Gemcitabine and Nab‐Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial
por: Ko, Andrew H., et al.
Publicado: (2017)

Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab‐Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results
por: O'Reilly, Eileen M., et al.
Publicado: (2017)

Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib with Concurrent Radiation for Newly Diagnosed Resectable Rectal Cancer
por: Araujo‐Mino, Emilio P., et al.
Publicado: (2017)

Predictors of Response and Survival in Locally Advanced Adenocarcinoma of the Pancreas Following Neoadjuvant GTX with or Without Radiation Therapy
por: Sherman, William H., et al.
Publicado: (2017)

Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma
por: Ghiaseddin, Ashley, et al.
Publicado: (2017)

Phase I Pharmacokinetic Study of Nivolumab in Korean Patients with Advanced Solid Tumors
por: Lee, Keun‐Wook, et al.
Publicado: (2017)

Phase II Study of Panitumumab in RAS Wild‐Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater
por: Gulhati, Pat, et al.
Publicado: (2017)

Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor‐Naïve Advanced Pancreatic Neuroendocrine Tumors
por: Salazar, Ramon, et al.
Publicado: (2017)

Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck
por: Trieu, Vanessa, et al.
Publicado: (2018)

A Phase II Study of Tumor Ablation in Patients with Metastatic Sarcoma Stable on Chemotherapy
por: Hirbe, Angela C., et al.
Publicado: (2018)

Pantoprazole, an Inhibitor of the Organic Cation Transporter 2, Does Not Ameliorate Cisplatin‐Related Ototoxicity or Nephrotoxicity in Children and Adolescents with Newly Diagnosed Osteosarcoma Treated with Methotrexate, Doxorubicin, and Cisplatin
por: Fox, Elizabeth, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_oeu16jaoqlethhcbcj77mpink1